An Open Label safety Extension study of olesoxime (TRO19622) in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole.

Trial Profile

An Open Label safety Extension study of olesoxime (TRO19622) in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Olesoxime (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Roche; Trophos
  • Most Recent Events

    • 22 Jun 2013 Planned number of patients changed from 271 to 350 as reported by United Kingdom Clinical Research Network.
    • 22 Jun 2013 New source identified and integrated (United Kingdom Clinical Research Network: 10407).
    • 09 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top